Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02731729 · ClinicalTrials.gov registry record · Phase 2
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
A Phase 2 study of Melanoma, sponsored by Parker Institute for Cancer Immunotherapy.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT02731729 is a Phase 2 study of Melanoma that has completed, run by Parker Institute for Cancer Immunotherapy. The registered enrollment target is 20 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT02731729, a Phase 2 study of Melanoma, has completed, sponsored by Parker Institute for Cancer Immunotherapy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this research study is to learn whether patients whose disease grows after being treated with nivolumab or pembrolizumab respond to ipilimumab (Yervoy®) alone or in combination with nivolumab (Opdivo®).
Conditions Studied
Interventions
- DRUG nivolumab
- DRUG ipilimumab
Study Locations (7)
California
- University of California, Los Angeles - Los Angeles
- University of California, San Francisco - San Francisco
New York
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Lehigh Valley Health Network - Allentown
- University of Pennsylvania - Philadelphia
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-06-21 |
| Est. Completion | 2019-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02731729
The ClinicalTrials.gov registry entry for NCT02731729 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (97% lower). The listed sponsor is Parker Institute for Cancer Immunotherapy, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which nivolumab is the first listed.
NCT02731729 reports 7 study locations spanning 4 distinct geographic areas - top geographies include California, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02731729 about?
NCT02731729 is a clinical study titled "Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy". The purpose of this research study is to learn whether patients whose disease grows after being treated with nivolumab or pembrolizumab respond to ipilimumab (Yervoy®) alone or in combination with nivolumab (Opdivo®).
What is the current status of trial NCT02731729?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-06-21. Estimated completion is 2019-02-13.
What conditions does trial NCT02731729 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT02731729?
The interventions under investigation include: nivolumab (DRUG), ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02731729?
This trial is sponsored by Parker Institute for Cancer Immunotherapy, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02731729 being conducted?
This trial has 7 study locations across California, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.